Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 321 to 330 of 369 total matches.

Comparison Table: Some FDA-Approved Drugs for Weight Management (online only)

   
The Medical Letter on Drugs and Therapeutics • May 30, 2022  (Issue 1651)
of a pound per week compared to placebotreated patients ▶ Limited data with longer use ▶ Phentermine ...
View the Comparison Table: Some FDA-Approved Drugs for Weight Management
Med Lett Drugs Ther. 2022 May 30;64(1651):e89-91 |  Show IntroductionHide Introduction

Deucravacitinib (Sotyktu) for Plaque Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023  (Issue 1670)
AND LACTATION — There are no adequate data on the use of deucravacitinib in pregnant or lactating women ...
The FDA has approved deucravacitinib (Sotyktu – BMS), an oral tyrosine kinase 2 (TYK2) inhibitor, for once-daily treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Deucravacitinib is the first selective TYK2 inhibitor to be approved in the US for any indication.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):29-31   doi:10.58347/tml.2023.1670b |  Show IntroductionHide Introduction

Zavegepant (Zavzpret) for Acute Treatment of Migraine

   
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023  (Issue 1681)
of migraine has been associated with an increased risk of hypertension.9 PREGNANCY AND LACTATION ― No data ...
The FDA has approved zavegepant nasal spray (Zavzpret – Pfizer) for acute treatment of migraine with or without aura in adults. Zavzpret is the first nasal spray formulation of a calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant") to become available in the US.
Med Lett Drugs Ther. 2023 Jul 24;65(1681):116-8   doi:10.58347/tml.2023.1681c |  Show IntroductionHide Introduction

Zuranolone (Zurzuvae) – An Oral Drug for Postpartum Depression

   
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023  (Issue 1692)
(SNRIs) and tricyclic antidepressants have also been used, but data on their efficacy are limited ...
The FDA has approved the oral GABAA receptor modulator zuranolone (Zurzuvae – Sage Therapeutics/Biogen) for treatment of postpartum depression (PPD). Zuranolone is the second drug to be approved for this indication; brexanolone (Zulresso), another GABAA receptor modulator, was approved for IV treatment of PPD in 2019.
Med Lett Drugs Ther. 2023 Dec 25;65(1692):201-3   doi:10.58347/tml.2023.1692a |  Show IntroductionHide Introduction

Roflumilast Foam (Zoryve) for Seborrheic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024  (Issue 1700)
trials with active controls are needed. Until comparative data become available, less expensive drugs ...
The FDA has approved a 0.3% foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of seborrheic dermatitis in patients ≥9 years old. Roflumilast is the first PDE4 inhibitor to be approved in the US for this indication. It is also available in a 0.3% cream formulation (Zoryve) for treatment of plaque psoriasis and in an oral formulation (Daliresp, and generics) for treatment of chronic obstructive pulmonary disease. A 0.15% cream formulation for treatment of atopic dermatitis in patients ≥6 years old will be reviewed...
Med Lett Drugs Ther. 2024 Apr 15;66(1700):57-9   doi:10.58347/tml.2024.1700a |  Show IntroductionHide Introduction

Elafibranor (Iqirvo) for Primary Biliary Cholangitis

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024  (Issue 1718)
is recommended during elafibranor treatment and for 3 weeks after the last dose. No data are available ...
Elafibranor (Iqirvo – Ipsen), a peroxisome proliferator-activated receptor (PPAR) agonist, has been granted accelerated approval by the FDA for treatment of primary biliary cholangitis (PBC) in adults. It is indicated for use in combination with ursodeoxycholic acid (ursodiol, UDCA; Urso, and others) in patients with an inadequate response to UDCA alone and as monotherapy in those unable to tolerate UDCA.
Med Lett Drugs Ther. 2024 Dec 23;66(1718):202-4   doi:10.58347/tml.2024.1718b |  Show IntroductionHide Introduction

A New RSV Vaccine (mResvia) for Adults ≥60 Years Old

   
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024  (Issue 1713)
. Follow-up data suggest that one dose of mResvia may offer less protection over two RSV seasons than one ...
TThe FDA has licensed mResvia (Moderna), an mRNA respiratory syncytial virus (RSV) vaccine, for prevention of lower respiratory tract disease (LRTD) caused by RSV in adults ≥60 years old. It is the first mRNA vaccine to be licensed in the US for this indication. Two recombinant RSV vaccines, Arexvy and Abrysvo, are also available for prevention of RSV LRTD. Arexvy is approved for use in adults ≥50 years old. Abrysvo is approved for use in adults ≥60 years old and in pregnant women to prevent RSV LRTD in their infants.
Med Lett Drugs Ther. 2024 Oct 14;66(1713):166-8   doi:10.58347/tml.2024.1713d |  Show IntroductionHide Introduction

Ponesimod (Ponvory) for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021  (Issue 1630)
with an increased risk of SARS-CoV-2 infection or development of severe COVID-19, but data are limited.9 In one ...
The FDA has approved ponesimod (Ponvory – Janssen), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Ponesimod is the fourth oral S1P receptor modulator to be approved in the US for once-daily treatment of relapsing forms of MS; ozanimod (Zeposia) and siponimod (Mayzent) are also approved for use in adults, and fingolimod (Gilenya) is indicated for use in patients...
Med Lett Drugs Ther. 2021 Aug 9;63(1630):123-5 |  Show IntroductionHide Introduction

Ibrexafungerp (Brexafemme) for Vulvovaginal Candidiasis

   
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021  (Issue 1632)
and congenital anomalies.7,8 LACTATION — No data are available on the presence of ibrexafungerp in human breast ...
The FDA has approved ibrexafungerp (Brexafemme – Scynexis), a first-in-class triterpenoid antifungal ("fungerp"), for oral treatment of vulvovaginal candidiasis in postmenarchal females.
Med Lett Drugs Ther. 2021 Sep 6;63(1632):141-3 |  Show IntroductionHide Introduction

Atogepant (Qulipta) for Migraine Prevention

   
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021  (Issue 1636)
therapy is generally not recommended during pregnancy. No data on the use of atogepant in pregnant ...
Atogepant (Qulipta – Abbvie), an oral small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant"), has been approved by the FDA for prevention of episodic migraine in adults. It is the second oral CGRP receptor antagonist to be approved in the US for this indication; the first was rimegepant (Nurtec ODT), which is also approved for acute treatment of migraine. Parenteral CGRP monoclonal antibodies are approved for prevention of migraine (see Table 3).
Med Lett Drugs Ther. 2021 Nov 1;63(1636):169-71 |  Show IntroductionHide Introduction